ATRA
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (ATRA) has 9 SEC Form 4 filings (10 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 25, 2026.
Insiders have net bought $1.5M over the trailing 6 months. The largest single insider purchase in this window was $4.7M by 10% Owner EcoR1 Capital, LLC on May 7, 2026.
- Industry:Biotechnology
- CEO:Anhco Nguyen
- Employees:153
- HQ:South San Francisco, CA, US
- IPO:2014-10-16
Insider Buying
$4.7M
reported purchases (SEC code P)
Insider Selling
$3.2M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$73.6M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Grant-Huerta YaninaFirst filing | Chief Accounting Officer | Sale | 2,414 | $22K | May 20 | SEC ↗ |
Nguyen AnhCoFirst filing | President and CEO | Sale | 5,241 | $48K | May 20 | SEC ↗ |
Panacea Innovation LtdFirst filing | 10% Owner | Sale | 313,446 | $3.2M | May 11 | SEC ↗ |
| 10% Owner | Purchase | 507,407 | $4.7M | May 11 | SEC ↗ |
Related companies
Atara Biotherapeutics, Inc. is in the Healthcare sector.